ESTRO 2025 - Abstract Book

S604

Clinical - Breast

ESTRO 2025

Conclusion: The key result is the identification of a preselection criteria to better predict which patients could benefit from proton therapy in DIBH: female patients with indication for IMN RT, younger than or equal to 50 years old and with cardiac risk factors. This preselection is crucial to streamline treatment planning and avoid delays, given the complexity and time-consuming nature of plan comparisons.

Keywords: breath-hold, proton therapy, breast cancer

References: 1. Boersma LJ, Sattler MGA, Maduro JH, Bijker N, Essers M, van Gestel CMJ, Klaver YLB, Petoukhova AL, Rodrigues MF, Russell NS, van der Schaaf A, Verhoeven K, van Vulpen M, Schuit E, Langendijk JA. Model-Based Selection for Proton Therapy in Breast Cancer: Development of the National Indication Protocol for Proton Therapy and First Clinical Experiences. Clin Oncol (R Coll Radiol). 2022 Apr;34(4):247-257. doi: 10.1016/j.clon.2021.12.007. PMID: 34996684.